Alligator Bioscience to Present Positive Phase 2 Mitazalimab

Alligator Bioscience AB announced that two clinical abstracts on its lead drug candidate mitazalimab, a best- in-class CD40 agonist, in first line metastatic pancreatic cancer will be presented in a...

Related Keywords

Chicago , Illinois , United States , American , , American Society Of Clinical Oncology , Alligator Bioscience , Clinical Oncology , Annual Meeting , Objective Response Rate , Response Evaluation Criteria , Solid Tumors , Overall Survival ,